Table 2.
Characteristics of randomized clinical trials that were included in the systematic review
| Study, yref | Country | Number, sex (F/M) 1 | Age (y) | RCT1 design | Duration | Intervention group | Control group | Reported data | Notes about participants |
|---|---|---|---|---|---|---|---|---|---|
| Homayouni et al., 201827 | Iran | 60 (32F/28M) | 30–65 | Parallel | 6 wk | 500 mg/d hesperidin | 500 mg/d starch | FBG1 HOMA‐IR1 | Patients with diabetes |
| int1: 51.3 | |||||||||
| con1: 54 | |||||||||
| Salden et al., 201637 | Germany | 68 (39F/29M) | 18–65 | Parallel | 6 wk | 450 mg/d hesperidin | 500 mg/d cellulose | FBG insulin QUICKI1 | Healthy overweight individuals |
| Int: 54 | |||||||||
| Con: 53 | |||||||||
| Rangel‐Huerta et al., 201538 | Spain | 100 F/M | 18–65 | Cross‐over | 12 wk | 500 ml/d high polyphenol juice hesperidin: 582.5 mg | 500 ml/d normal polyphenol juice hesperidin: 237 mg | FBG insulin HOMA‐IR | Healthy overweight/obese individuals |
| Eghtesadi et al., 201526 | Iran | 45 F/M | Int: 53.2 | Parallel | 8 wk | 500 mg/d hesperidin | 500 mg/d cellulose | FBG insulin HOMA‐IR HbA1c1 | Patients with diabetes |
| Con: 53.4 | |||||||||
| Morand et al., 201140 | France | 24 (24 M) | 50–65 | Cross‐over | 4 wk | 500 ml of the control drink +292 mg hesperidin | 500 ml of the control drink +292 mg starch | FBG insulin | Healthy overweight individuals |
| Rizza et al., 201139 | Italy | 24 (9F/15M) | 21–65 | Cross‐over | 3 wk | 500 mg/d hesperidin | 500 mg/d cellulose | FBG insulin QUICKI HbA1c | Patients with metabolic syndrome |
| Int: 53 | |||||||||
| Con: 50 |
1
F: female, M: male, RCT: randomized controlled trial, Int: intervention, Con: control, FBG: fasting blood glucose, HOMA‐IR: homeostatic model assessment for insulin resistance, QUICKI: quantitative insulin sensitivity check index, HbA1c: haemoglobin A1c